Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials

Brief Report

(2017) José R. Arribas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2017) François Raffi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

(2017) Edwin DeJesus et al.   Lancet HIV

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

(2017) Chloe Orkin et al.   Lancet HIV

Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia

(2016) Pornpimol Thamrongwonglert et al.   HIV CLINICAL TRIALS

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

(2015) José R. Santos et al.   CLINICAL INFECTIOUS DISEASES

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy

(2015) Nathan Ford et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study

(2015) Nina Friis-Møller et al.   European Journal of Preventive Cardiology

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

(2014) Katie R. Mollan et al.   ANNALS OF INTERNAL MEDICINE

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy

(2013) Zara Shubber et al.   AIDS

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

(2013) David C. Goff et al.   CIRCULATION

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles

(2012) Georg Behrens et al.   ANTIVIRAL THERAPY

Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence

(2011) Andrew M. Hall et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

(2010) Marisa Tungsiripat et al.   AIDS

Efavirenz: a decade of clinical experience in the treatment of HIV

(2009) F. Maggiolo   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY